- More than 400 undergraduate and graduate students in
the U.S. have benefited from the AbbVie Immunology Scholarship
since its inception in 2016
NORTH
CHICAGO, Ill., Aug. 27,
2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today
announced the 2024-2025 recipients of the AbbVie Immunology
Scholarship, aimed to support students living with chronic,
inflammatory diseases as they pursue higher education.
Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/9253951-abbvie-immunology-scholarship-2024-2025-recipients/
Due to the constraints of living with chronic illness, research
finds that young adults with childhood-onset chronic illness have
statistically lower rates of high school and college
graduation.1 To honor the determination of these
students, the AbbVie Immunology Scholarship strives to ease the
financial burden and empower students to achieve their personal and
academic aspirations.
"AbbVie is deeply committed to caring for the whole patient in
immunology," said Jérôme Bouyer, senior vice president and
president of Immunology at AbbVie, "We are honored to support
students as they pursue their academic journeys and strive toward a
life beyond the constraints of their immune-mediated
conditions."
AbbVie awarded scholarships to 45 recipients split equally among
dermatology, gastroenterology and rheumatology therapeutic areas.
Qualified applicants were selected based on academic excellence,
community leadership, essay submission and recommendation letters.
By investing in their education, AbbVie intends to promote
resilience and inspire hope for a future beyond their disease.
"Receiving the AbbVie Immunology Scholarship is more than just
financial support; it is a profound validation of my dedication to
achieving my personal and professional goals despite the daily
battle with an inflammatory disease," said LaWanda McCraney, 2024-2025 scholarship
recipient and PhD candidate at Adler University. "This scholarship
is a testament to the potential impact of my work and the
importance of perseverance in the face of challenges."
Students living with immune-mediated conditions across
dermatology, gastroenterology and rheumatology seeking an
associate, bachelor's, master's or doctorate degree are eligible to
apply for the AbbVie Immunology Scholarship. Those interested in
applying for the 2025-2026 scholarship period, can sign up
here to be notified when the application period opens.
Interested students can explore eligibility criteria and apply
on the newly relaunched website,
www.AbbVieImmunologyScholarship.com.
About the AbbVie Immunology Scholarship
The AbbVie Immunology Scholarship provides financial support to
exceptional students living with inflammatory diseases and pursuing
higher education in the United
States. Through this scholarship, AbbVie's passion for
patient care is extended to empower students as they pursue a
degree and a life not defined by their disease. It is not necessary
for scholarship applicants to have taken, currently take, or intend
to take in the future, any medicine or product marketed by AbbVie,
and this is not a consideration in the selection criteria. Visit
https://www.abbvieimmunologyscholarship.com/ to learn
more.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience, and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
LinkedIn, Facebook, Instagram, X (formerly Twitter), and
YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions and uses
of future or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2023 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
References
- Maslow, G. R., Haydon, A., McRee, A.-L., Ford, C. A., &
Halpern, C. T. (2011). "Growing Up With a Chronic Illness: Social
Success, Educational/Vocational Distress". Journal of
Adolescent Health, 49(2), 206–212.
https://doi.org/10.1016/j.jadohealth.2010.12.001
US-IMM-240094
View original
content:https://www.prnewswire.com/news-releases/abbvie-awards-scholarships-to-45-us-students-living-with-chronic-immune-mediated-diseases-302230956.html
SOURCE AbbVie